Product Development Pipeline (Detail)	9 Months Ended
	Sep. 30, 2012
Androxal [Member] | Secondary Hypogonadism [Member]
Product Information [Line Items]
Status	Phase 3
Next Expected Milestone(s)	Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014)
Proellex [Member] | Uterine Fibroids [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Complete Phase 2 study (vaginal delivery) (Q4 2012) Commence Phase 3 study (vaginal delivery) (Q1 2013)
Proellex [Member] | Endometriosis [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Initiate Phase 2 study (oral delivery) (Q4 2012)